{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:45:03Z","timestamp":1792763103762,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332019048"],"award-info":[{"award-number":["3332019048"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400187"],"award-info":[{"award-number":["81400187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.amjms.2021.01.009","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T09:15:42Z","timestamp":1610615742000},"page":"260-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prevalence and Clinical Characteristics of Fabry Disease in Chinese Patients With Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"362","author":[{"given":"Yan","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran-Xu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Xia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Liang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2021.01.009_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding andtreatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"4","key":"10.1016\/j.amjms.2021.01.009_bib0002","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view","volume":"112","author":"Hagege","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.amjms.2021.01.009_bib0003","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.amjms.2021.01.009_bib0004","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int J Cardiol"},{"issue":"FI2","key":"10.1016\/j.amjms.2021.01.009_bib0005","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"issue":"Suppl 2","key":"10.1016\/j.amjms.2021.01.009_bib0006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1012428009627","article-title":"Cardiac manifestations in Fabry disease","volume":"24","author":"Linhart","year":"2001","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"10.1016\/j.amjms.2021.01.009_bib0007","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2021.01.009_bib0008","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.2147\/DDDT.S207856","article-title":"Cardio- Renal outcomes with long- term agalsidase alfa enzyme replacement therapy: a 10- year Fabry Outcome Survey (FOS) analysis","volume":"13","author":"Ramaswami","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.amjms.2021.01.009_bib0009","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.amjms.2021.01.009_bib0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"issue":"23","key":"10.1016\/j.amjms.2021.01.009_bib0011","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.amjms.2021.01.009_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2017.09.010","article-title":"Identification of Fabry disease in a tertiary referral cohort of patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"issue":"25","key":"10.1016\/j.amjms.2021.01.009_bib0013","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.amjms.2021.01.009_bib0014","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.amjms.2021.01.009_bib0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjms.2021.01.009_bib0016","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017","volume":"55","author":"Doheny","year":"2018","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.amjms.2021.01.009_bib0017","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jjcc.2016.05.014","article-title":"Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy","volume":"69","author":"Kubo","year":"2017","journal-title":"J Cardiol"},{"issue":"39","key":"10.1016\/j.amjms.2021.01.009_bib0018","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjms.2021.01.009_bib0019","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12967-018-1605-5","article-title":"Molecular analysis of inherited cardiomyopathy using next generation semiconductor sequencing technologies","volume":"16","author":"Lu","year":"2018","journal-title":"J Transl Med"},{"issue":"21-22","key":"10.1016\/j.amjms.2021.01.009_bib0020","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.cca.2010.06.023","article-title":"Quantification of alpha-galactosidase activity in intact leukocytes","volume":"411","author":"Holzl","year":"2010","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1016\/j.amjms.2021.01.009_bib0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.amjms.2021.01.009_bib0022","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.amjms.2021.01.009_bib0023","first-page":"883","article-title":"Clinical features, diagnosis, and management of patients with anderson-Fabry cardiomyopathy","volume":"33","author":"Yogasundaram","year":"2017","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.amjms.2021.01.009_bib0024","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"23","key":"10.1016\/j.amjms.2021.01.009_bib0025","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.amjms.2021.01.009_bib0026","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular involvement in Fabry disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"10.1016\/j.amjms.2021.01.009_bib0027","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.echo.2016.11.014","article-title":"Right ventricular hypertrophy, systolic function, and disease severity in Anderson-Fabry disease: an echocardiographic study","volume":"30","author":"Graziani","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"10.1016\/j.amjms.2021.01.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157565","article-title":"Reduced right ventricular native myocardial T1 in Anderson-Fabry disease: comparison to pulmonary hypertension and healthy controls","volume":"11","author":"Pagano","year":"2016","journal-title":"PLoS One"},{"issue":"7 Pt 1","key":"10.1016\/j.amjms.2021.01.009_bib0029","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","article-title":"The role of cardiac imaging in the diagnosis and management of Anderson-Fabry disease","volume":"12","author":"Perry","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.amjms.2021.01.009_bib0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8175.2005.03191.x","article-title":"Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male","volume":"22","author":"Magage","year":"2005","journal-title":"Echocardiography"},{"issue":"2","key":"10.1016\/j.amjms.2021.01.009_bib0031","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/000331970605700217","article-title":"Relief of left ventricular outflow obstruction by cibenzoline in a patient with Fabry's disease\u2013a case report","volume":"57","author":"Morimoto","year":"2006","journal-title":"Angiology"},{"issue":"1","key":"10.1016\/j.amjms.2021.01.009_bib0032","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacc.2011.03.020","article-title":"Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease","volume":"58","author":"Calcagnino","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2021.01.009_bib0033","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.06.042","article-title":"Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease","volume":"292","author":"Meghji","year":"2019","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.amjms.2021.01.009_bib0034","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease","volume":"13","author":"O'Mahony","year":"2011","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.amjms.2021.01.009_bib0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.2010.200188","article-title":"Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study","volume":"97","author":"Hagege","year":"2011","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.amjms.2021.01.009_bib0036","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cpt.1536","article-title":"Oral chaperone therapy migalastat for the treatment of Fabry disease: potentials and pitfalls of real-world data","volume":"106","author":"Korver","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.amjms.2021.01.009_bib0037","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.amjms.2021.01.009_bib0038","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS \u2013 Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.amjms.2021.01.009_bib0039","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.amjms.2021.01.009_bib0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MOT.0000000000000756","article-title":"Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis","volume":"25","author":"Di Nora","year":"2020","journal-title":"Curr Opin Organ Transpl"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962921000094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962921000094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:15:41Z","timestamp":1762082141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962921000094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0002962921000094"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2021.01.009","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and Clinical Characteristics of Fabry Disease in Chinese Patients With Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2021.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.","name":"copyright","label":"Copyright"}]}}